Celera links up with LabCorp and Quest:
This article was originally published in Clinica
Executive Summary
Celera Diagnostics has formed separate deals with Laboratory Corporation of America (LabCorp) and Quest Diagnostics to collaborate on tests for a number of common diseases. The agreement with LabCorp is expected to lead to tests for Alzheimer's disease, breast cancer and prostate cancer. The deal with Quest provides for the development of tests for cardiovascular disease and diabetes. The collaborations will support current and future disease association studies at Celera that seek to identify genetic markers associated with the diseases. Alameda, California-based Celera will be the preferred vendor to LabCorp and Quest for certain molecular diagnostic products.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.